(Q34072167)

English

Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

attention deficit hyperactivity disorder

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Raveen Hanwella

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Madhri Senanayake

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Varuni de Silva

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

10 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

176

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Comparing the efficacy of medications for ADHD using meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Effects of atomoxetine and methylphenidate on sleep in children with ADHD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

The worldwide prevalence of ADHD: is it an American condition?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Attention-deficit/hyperactivity disorder: a selective overview

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Bupropion hydrochloride in attention deficit disorder with hyperactivity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Medication and Hyperactivity: A Meta-Analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

The efficacy of stimulant drug treatment for hyperactivity: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Meta-analysis in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

5 July 2018

Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

Incorporating variations in the quality of individual randomized trials into meta-analysis.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

[Benefit of the extended-release methylphenidate formulations: a comparative study in childhood]

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

Meta-analysis of suicide-related behavior events in patients treated with atomoxetine

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-11-176

21 January 2018

Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

28 October 2018

Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder--United States, 2003.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

28 October 2018

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3229459

28 October 2018

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD

1 reference

https://pubmed.ncbi.nlm.nih.gov/22074258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical Practice Guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity Disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/22074258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22074258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-244X-11-176

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34072167&oldid=2196202937"